Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Does The Orphan Drug Act Need A Facelift? Advocates Consider Changes

Executive Summary

Rare disease advocates are wondering whether it may be time to strengthen the Orphan Drug Act and at least one organization is researching potential improvements that could be made to the pathway.
Advertisement

Related Content

Orphan Drug Prices To Face Fiscal Cliff Scrutiny, NORD Expects
NORD Says Orphan Drug Act Is Fine As Is, Wants To Work For Improvements Within System
Orphan Drugs Need Easier, Speedier Approval, Not More Exclusivity, CEO Says
FDA Steps Into Makena Pricing Dispute In The Name Of "Access"
Orphan Drugs Warrant Flexibility On Clinical Pharmacology Data, FDA Panel Says
Orphan Drugs Warrant Flexibility On Clinical Pharmacology Data, FDA Panel Says
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue
FDA To Offer Reviewers Rare Disease Training; Patient Groups Want Separate ODE
Orphan Drug Reviews: Industry Wants FDA To Move Out Of Its Comfort Zone

Topics

Advertisement
UsernamePublicRestriction

Register

PS053225

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel